Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  9/10/2013
Clinical Research Facility
mi
from
Dallas, TX
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 9/10/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  9/10/2013
Clinical Research Facility
mi
from
San Antonio, TX
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 9/10/2013
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study
The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study
Status: Enrolling
Updated:  9/13/2013
College of Optometry
mi
from
Columbus, OH
The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study
The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study
Status: Enrolling
Updated: 9/13/2013
College of Optometry
mi
from
Columbus, OH
Click here to add this to my saved trials
FiteBac Hand Sanitizer in the Management of Hand Dermatitis in Adults
A One Month, Randomized, Two-center, Parallel-group, Double-blind,Placebo-controlled Study to Evaluate the Efficacy and Safety of FiteBac Hand Sanitizer TID vs Emollient Therapy in the Management of Hand Dermatitis in Adults
Status: Enrolling
Updated:  9/23/2013
National Jewish Health
mi
from
Denver, CO
FiteBac Hand Sanitizer in the Management of Hand Dermatitis in Adults
A One Month, Randomized, Two-center, Parallel-group, Double-blind,Placebo-controlled Study to Evaluate the Efficacy and Safety of FiteBac Hand Sanitizer TID vs Emollient Therapy in the Management of Hand Dermatitis in Adults
Status: Enrolling
Updated: 9/23/2013
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated:  9/30/2013
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated: 9/30/2013
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated:  9/30/2013
Weill Cornell Breast Center
mi
from
New York, NY
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated: 9/30/2013
Weill Cornell Breast Center
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated:  9/30/2013
Beth Israel Medical Center, Comprehensive Cancer Center
mi
from
New York, NY
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated: 9/30/2013
Beth Israel Medical Center, Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated:  9/30/2013
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia
Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer
Status: Enrolling
Updated: 9/30/2013
Wake Forest University School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy
A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy
Status: Enrolling
Updated:  10/21/2013
Bodian Dermatology
mi
from
Great Neck, NY
A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy
A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy
Status: Enrolling
Updated: 10/21/2013
Bodian Dermatology
mi
from
Great Neck, NY
Click here to add this to my saved trials
A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy
A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy
Status: Enrolling
Updated:  10/21/2013
Center for Aesthetic Dermatology
mi
from
Woodbury, NY
A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy
A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy
Status: Enrolling
Updated: 10/21/2013
Center for Aesthetic Dermatology
mi
from
Woodbury, NY
Click here to add this to my saved trials
Alopecia Areata Registry and Immunogenetic Mechanisms
Alopecia Areata Registry and Immunogenetic Mechanisms
Status: Enrolling
Updated:  11/20/2013
Univ of Minnesota
mi
from
Minneapolis, MN
Alopecia Areata Registry and Immunogenetic Mechanisms
Alopecia Areata Registry and Immunogenetic Mechanisms
Status: Enrolling
Updated: 11/20/2013
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated:  11/25/2013
Dermatology Research Associates
mi
from
Los Angeles, CA
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated: 11/25/2013
Dermatology Research Associates
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated:  11/25/2013
Therapeutics Clinical Research
mi
from
San Diego, CA
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated: 11/25/2013
Therapeutics Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated:  11/25/2013
University Clinical Trials, Inc.
mi
from
San Diego, CA
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated: 11/25/2013
University Clinical Trials, Inc.
mi
from
San Diego, CA
Click here to add this to my saved trials
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated:  11/25/2013
International Clinical Research - US, LLC
mi
from
Sanford, FL
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated: 11/25/2013
International Clinical Research - US, LLC
mi
from
Sanford, FL
Click here to add this to my saved trials
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated:  11/25/2013
Gwinnett Clinical Research Center, Inc
mi
from
Snellville, GA
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated: 11/25/2013
Gwinnett Clinical Research Center, Inc
mi
from
Snellville, GA
Click here to add this to my saved trials
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated:  11/25/2013
Altman Dermatology Associates
mi
from
Arlington Heights, IL
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated: 11/25/2013
Altman Dermatology Associates
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated:  11/25/2013
The Indiana Clinical Trials Center, PC
mi
from
Plainfield, IN
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated: 11/25/2013
The Indiana Clinical Trials Center, PC
mi
from
Plainfield, IN
Click here to add this to my saved trials
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated:  11/25/2013
Marina I Peredo, MD
mi
from
Smithtown, NY
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated: 11/25/2013
Marina I Peredo, MD
mi
from
Smithtown, NY
Click here to add this to my saved trials
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated:  11/25/2013
Penn State Milton S. Hershey Medical Center - Dept. of Dermatology
mi
from
Hershey, PA
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated: 11/25/2013
Penn State Milton S. Hershey Medical Center - Dept. of Dermatology
mi
from
Hershey, PA
Click here to add this to my saved trials
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated:  11/25/2013
Clinical Partners, LLC
mi
from
Johnston, RI
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated: 11/25/2013
Clinical Partners, LLC
mi
from
Johnston, RI
Click here to add this to my saved trials
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated:  11/25/2013
J&S Studies
mi
from
College Station, TX
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated: 11/25/2013
J&S Studies
mi
from
College Station, TX
Click here to add this to my saved trials
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated:  11/25/2013
UT-Houston Health Science Center
mi
from
Houston, TX
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated: 11/25/2013
UT-Houston Health Science Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated:  11/25/2013
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris
A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Status: Enrolling
Updated: 11/25/2013
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Click here to add this to my saved trials
1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX
1% Topical Pimecrolimus Cream for the Prevention of Rash Associated With the Use of the EGFR Antagonist, Cetuximab
Status: Enrolling
Updated:  1/6/2014
West Virginia University Hospitals Mary Babb Randolph Cancer Center
mi
from
Morgantown, WV
1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX
1% Topical Pimecrolimus Cream for the Prevention of Rash Associated With the Use of the EGFR Antagonist, Cetuximab
Status: Enrolling
Updated: 1/6/2014
West Virginia University Hospitals Mary Babb Randolph Cancer Center
mi
from
Morgantown, WV
Click here to add this to my saved trials
Efficacy and Safety of CRTH2 Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines
A Phase IIa, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of the CRTH2 Antagonist AZD1981 in Patients With Chronic Idiopathic Urticaria (CIU) Who Are Refractory to H1 Antihistamines
Status: Enrolling
Updated:  1/24/2014
Johns Hopkins Asthma and Allergy Center
mi
from
Baltimore, MD
Efficacy and Safety of CRTH2 Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines
A Phase IIa, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of the CRTH2 Antagonist AZD1981 in Patients With Chronic Idiopathic Urticaria (CIU) Who Are Refractory to H1 Antihistamines
Status: Enrolling
Updated: 1/24/2014
Johns Hopkins Asthma and Allergy Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Comparison Between Interactive Internet-based Education and Counseling for the Management of Acne With That of Internet-based Education Alone
Comparison Between Interactive Internet-based Education and Counseling for the Management of Acne With That of Internet-based Education Alone
Status: Enrolling
Updated:  2/6/2014
University of California-Davis
mi
from
Sacramento, CA
Comparison Between Interactive Internet-based Education and Counseling for the Management of Acne With That of Internet-based Education Alone
Comparison Between Interactive Internet-based Education and Counseling for the Management of Acne With That of Internet-based Education Alone
Status: Enrolling
Updated: 2/6/2014
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis
Status: Enrolling
Updated:  2/20/2014
University of California at San Diego
mi
from
San Diego, CA
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis
Status: Enrolling
Updated: 2/20/2014
University of California at San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis
Status: Enrolling
Updated:  2/20/2014
University of California - San Francisco
mi
from
San Francisco, CA
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis
Status: Enrolling
Updated: 2/20/2014
University of California - San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis
Status: Enrolling
Updated:  2/20/2014
Stanford University School of Medicine
mi
from
Stanford, CA
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis
Status: Enrolling
Updated: 2/20/2014
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis
Status: Enrolling
Updated:  2/20/2014
Children's Memorial Hospital Division of Dermatology
mi
from
Chicago, IL
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis
Status: Enrolling
Updated: 2/20/2014
Children's Memorial Hospital Division of Dermatology
mi
from
Chicago, IL
Click here to add this to my saved trials
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis
Status: Enrolling
Updated:  2/20/2014
UMass Memorial Dermatology Center
mi
from
Worcester, MA
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis
Status: Enrolling
Updated: 2/20/2014
UMass Memorial Dermatology Center
mi
from
Worcester, MA
Click here to add this to my saved trials
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis
Status: Enrolling
Updated:  2/20/2014
Central Dermatology
mi
from
St. Louis, MO
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis
Status: Enrolling
Updated: 2/20/2014
Central Dermatology
mi
from
St. Louis, MO
Click here to add this to my saved trials
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis
Status: Enrolling
Updated:  2/20/2014
University Hospitals, Case Medical Centers
mi
from
Cleveland, OH
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis
Status: Enrolling
Updated: 2/20/2014
University Hospitals, Case Medical Centers
mi
from
Cleveland, OH
Click here to add this to my saved trials
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis
Status: Enrolling
Updated:  2/20/2014
Texas Dermatology Associates
mi
from
Dallas, TX
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis
Status: Enrolling
Updated: 2/20/2014
Texas Dermatology Associates
mi
from
Dallas, TX
Click here to add this to my saved trials
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis
Status: Enrolling
Updated:  2/20/2014
Texas Children's Hospital
mi
from
Houston, TX
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index and Comorbid Risk Factors: an Epidemiologic Analysis
Status: Enrolling
Updated: 2/20/2014
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
A Psychoeducational Prevention for the Treatment of Atopic Dermatitis in Youth and Their Families
A Multi-Disciplinary Psychoeducational Prevention for the Treatment of Atopic Dermatitis in Youth and Their Families: A Pilot Study
Status: Enrolling
Updated:  2/25/2014
'Specially for Children, Dell Children's Medical Center
mi
from
Austin, TX
A Psychoeducational Prevention for the Treatment of Atopic Dermatitis in Youth and Their Families
A Multi-Disciplinary Psychoeducational Prevention for the Treatment of Atopic Dermatitis in Youth and Their Families: A Pilot Study
Status: Enrolling
Updated: 2/25/2014
'Specially for Children, Dell Children's Medical Center
mi
from
Austin, TX
Click here to add this to my saved trials
Nanocytology Test to Evaluate Skin Cancer in High Risk Patients
Nanocytology Evaluation of Epidermal Cells to Assess Risk of Squamous Cell Carcinoma and Field Cancerization in High Risk Patients
Status: Enrolling
Updated:  2/27/2014
Northwestern Memorial Hospital
mi
from
Chicago, IL
Nanocytology Test to Evaluate Skin Cancer in High Risk Patients
Nanocytology Evaluation of Epidermal Cells to Assess Risk of Squamous Cell Carcinoma and Field Cancerization in High Risk Patients
Status: Enrolling
Updated: 2/27/2014
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Comparing OTC Acne Treatment to Prescription Regimen
A MULTI-CENTER, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF TWO ACNE CREAMS IN SUBJECTS WITH MILD TO MODERATE ACNE VULGARIS
Status: Enrolling
Updated:  3/24/2014
Penn State Hershey Medical Center
mi
from
Hershey, PA
Comparing OTC Acne Treatment to Prescription Regimen
A MULTI-CENTER, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF TWO ACNE CREAMS IN SUBJECTS WITH MILD TO MODERATE ACNE VULGARIS
Status: Enrolling
Updated: 3/24/2014
Penn State Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions
A Randomized, Double-blinded Study to Evaluate the Ability of an Acne Treatment Product to Produce Visible Improvements in Acne Lesions Over a 5 Day Period of Once-daily Use
Status: Enrolling
Updated:  4/10/2014
Dermatology Consulting Services - NC
mi
from
High Point, NC
A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions
A Randomized, Double-blinded Study to Evaluate the Ability of an Acne Treatment Product to Produce Visible Improvements in Acne Lesions Over a 5 Day Period of Once-daily Use
Status: Enrolling
Updated: 4/10/2014
Dermatology Consulting Services - NC
mi
from
High Point, NC
Click here to add this to my saved trials
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  4/18/2014
Clinical Research Facility
mi
from
Phoenix, AZ
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 4/18/2014
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  4/18/2014
Clinical Research Facility
mi
from
Bakersfield, CA
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 4/18/2014
Clinical Research Facility
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  4/18/2014
Clinical Research Facility
mi
from
Fremont, CA
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 4/18/2014
Clinical Research Facility
mi
from
Fremont, CA
Click here to add this to my saved trials
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  4/18/2014
Clinical Research Facility
mi
from
Los Angeles, CA
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 4/18/2014
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  4/18/2014
Clinical Research Facility
mi
from
San Diego, CA
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 4/18/2014
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  4/18/2014
Clinical Research Facility
mi
from
San Francisco, CA
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 4/18/2014
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  4/18/2014
Clinical Research Facility
mi
from
Miami, FL
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 4/18/2014
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  4/18/2014
Clinical Research Facility
mi
from
Orange Park, FL
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 4/18/2014
Clinical Research Facility
mi
from
Orange Park, FL
Click here to add this to my saved trials
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  4/18/2014
Clinical Research Facility
mi
from
Ormond Beach, FL
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 4/18/2014
Clinical Research Facility
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  4/18/2014
Clinical Research Facility
mi
from
Tampa, FL
Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 4/18/2014
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials